NAPLEX HIV Exams · Practice Exam 1
50 NAPLEX-style HIV questions focused on ART selection, major brand-name combinations, drug interactions, PrEP/PEP, opportunistic-infection prophylaxis, monitoring, and medication safety. Includes Study + Timed modes with full explanations for every question.
- 50 Questions
- 80 Minutes
- Study + Timed
- 39 SBA · 8 SATA · 3 Numeric
- Save & Resume
- Exam Tools
What this exam covers
Thirty-nine single-best-answer items with five options, eight select-all-that-apply items and three numeric fill-in items. Initial ART selection and rapid start; hepatitis B coinfection and why a complete regimen matters; HLA-B*5701 and abacavir; the major single-tablet brands and their components, including Biktarvy, Triumeq, Delstrigo, Odefsey, Complera, Genvoya, Stribild and Symtuza; two-drug regimens and their limits; long-acting injectables; entry, attachment and capsid inhibitors; acid-suppression and polyvalent-cation interactions; boosted-PI and cobicistat interactions including statin safety; PrEP across Truvada, Descovy, Apretude and Yeztugo with their product-specific restrictions; nPEP timing, regimen and duration; the CDC laboratory diagnostic algorithm and acute infection; opportunistic-infection prophylaxis thresholds and the stop and restart rules; treatment of Pneumocystis pneumonia and CMV disease with the medication-safety decisions they force; renal and bone considerations across TDF and TAF; and the calculations behind creatinine clearance, intrapartum zidovudine and a PEP course.
Included with eligible RxBoardPrep NAPLEX programs. Back to NAPLEX HIV Exams
RxBoardPrep practice exams are independent educational study material. They are not affiliated with, endorsed by, or produced by NABP, they are not official NAPLEX questions, and the stated timing is RxBoardPrep practice timing rather than official examination timing.